Mid-Cap
Rivian Beats Expectations, Targets Major Delivery Growth With Launch of R2 SUV
Electric vehicle maker shows financial progress but warns losses will continue during next phase of expansion Rivian Automotive (RIVN) delivered...
FDA Approves Novocure’s Optune Pax®, Marking Major Breakthrough in Pancreatic Cancer Treatment
First new therapy in nearly 30 years delivers survival benefit using innovative electric field technology The U.S. Food and Drug...
Viking Therapeutics Moves Oral Obesity Drug Into Late-Stage Development
Company advances VKTX program as competition intensifies in the rapidly expanding weight-loss market Viking Therapeutics (VKTX) announced Wednesday that it...
Dentsply Sirona’s $45 Bull Case: A Turnaround Leveraged to a Dental Recovery
If demand stabilizes, cost savings stick, and digital/aligners re-accelerate, XRAY could re-rate sharply Dentsply Sirona (XRAY) has been treated like...
KULR Technology: The Market Trades Bitcoin — I’m Watching the Battery Business
The big picture Over the past year, KULR’s stock has behaved more like a Bitcoin proxy than a niche industrial...
Callan JMB and Attune Biotech Form Strategic Alliance to Accelerate Federal Medical Deployments
Teaming agreement positions Attune’s pipeline for immediate Strategic National Stockpile readiness while unlocking up to $75 million in shared revenue....
Rick Sparkle Holdings Soars 115% as Speculation and Momentum Collide
Thin float, heavy volume, and catalyst-driven trading ignite a sharp rally in ANPA shares Shares of Rick Sparkle Holdings (ANPA)...
flyExclusive Elevates Private Aviation Connectivity With Starlink Deal
Authorized dealership positions the jet operator at the forefront of in-flight internet and MRO services flyExclusive (FLYX) is raising the...
Rivian Bets on Vertical Integration to Power Its Autonomous Future
CEO RJ Scaringe outlines the EV maker’s AI-driven roadmap toward personal Level 4 autonomy At Rivian’s (RIVN) Autonomy and AI...
Processa Pharmaceuticals Reports Promising Phase 2 Results for Breast Cancer Therapy
NGC-Cap shows enhanced cancer-killing exposure with comparable safety ahead of 2026 interim analysis Processa Pharmaceuticals (PCSA) provided a positive clinical...
